Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists (Q37775612)

https://api.crossref.org/works/10.2165%2F11533230-000000000-00000

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533230-000000000-00000

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533230-000000000-00000

Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533230-000000000-00000

Anxiety and depression in later life: Co-occurrence and communality of risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533230-000000000-00000

The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats

21 January 2018

1 reference

12 December 2020

N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells

1 reference

12 December 2020

In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling

1 reference

12 December 2020

Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling

1 reference

12 December 2020

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors

1 reference

12 December 2020

Ketamine and the potential role for rapid-acting antidepressant medications.

1 reference

12 December 2020

Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.

1 reference

12 December 2020

Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study

1 reference

12 December 2020

An open trial of topiramate in the treatment of generalized social phobia.

1 reference

12 December 2020

Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography

1 reference

12 December 2020

Regulation of phosphorylation of NMDA receptor NR1 subunits in the rat neostriatum by group I metabotropic glutamate receptors in vivo

1 reference

12 December 2020

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

1 reference

12 December 2020

A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia

1 reference

12 December 2020

Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits

1 reference

12 December 2020

Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population

1 reference

12 December 2020

Open-label trial of riluzole in generalized anxiety disorder

1 reference

12 December 2020

Recent progress in the development of allosteric modulators of mGluR5.

1 reference

12 December 2020

De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia

1 reference

12 December 2020

Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia

1 reference

12 December 2020

Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex

1 reference

12 December 2020

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

1 reference

12 December 2020

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

1 reference

12 December 2020

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis

1 reference

12 December 2020

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

1 reference

12 December 2020

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

1 reference

12 December 2020

Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice.

1 reference

12 December 2020

Induction of LTD by activation of group I mGluR in the dentate gyrus in vitro

1 reference

12 December 2020

Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats

1 reference

12 December 2020

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex

1 reference

12 December 2020

The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist.

1 reference

12 December 2020

Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling

1 reference

12 December 2020

Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia

1 reference

12 December 2020

Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial

1 reference

12 December 2020

Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxioly

1 reference

12 December 2020

Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models

1 reference

12 December 2020

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models

1 reference

12 December 2020

Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.

1 reference

12 December 2020

Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action.

1 reference

12 December 2020

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

1 reference

12 December 2020

A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population

1 reference

12 December 2020

Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740.

1 reference

12 December 2020

Animal models and treatments for addiction and depression co-morbidity

1 reference

12 December 2020

The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats

1 reference

12 December 2020

Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population

1 reference

12 December 2020

Identification of a serotonin/glutamate receptor complex implicated in psychosis

1 reference

12 December 2020

MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

1 reference

12 December 2020

Antidepressant-like actions of minocycline combined with several glutamate antagonists

1 reference

12 December 2020

Estrus variation in anticonflict-like effects of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of female Wistar rats

1 reference

12 December 2020

Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat.

1 reference

12 December 2020

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia

1 reference

12 December 2020

NMDA receptors and schizophrenia.

1 reference

12 December 2020

mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity

1 reference

12 December 2020

The origin and neuronal function of in vivo nonsynaptic glutamate.

1 reference

12 December 2020

The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety

1 reference

12 December 2020

Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions

1 reference

12 December 2020

The role of group I metabotropic glutamate receptors in schizophrenia

1 reference

12 December 2020

Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine

1 reference

12 December 2020

Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons.

1 reference

12 December 2020

Mutation screening of the metabotropic glutamate receptor mGluR4 (GRM4) gene in patients with schizophrenia

1 reference

12 December 2020

Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation

1 reference

12 December 2020

Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors

1 reference

12 December 2020

Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats

1 reference

12 December 2020

Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice

1 reference

12 December 2020

A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity

1 reference

12 December 2020

High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam

1 reference

12 December 2020

Metabotropic glutamate receptors

1 reference

12 December 2020

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

1 reference

12 December 2020

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

1 reference

12 December 2020

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear

1 reference

12 December 2020

The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats

1 reference

12 December 2020

Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia

1 reference

12 December 2020

Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice.

1 reference

12 December 2020

Metabotropic glutamate receptors in the control of mood disorders

1 reference

12 December 2020

Glutamate and anxiety disorders

1 reference

12 December 2020

Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats

1 reference

12 December 2020

Comparative pharmacology of bipolar disorder and schizophrenia

1 reference

12 December 2020

The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats

1 reference

12 December 2020

Effect of MPEP treatment on brain-derived neurotrophic factor gene expression.

1 reference

12 December 2020

Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety

1 reference

12 December 2020

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxyli

1 reference

12 December 2020

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

1 reference

12 December 2020

Glutamate Carboxypeptidase II Gene Expression in the Human Frontal and Temporal Lobe in Schizophrenia

1 reference

12 December 2020

Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats

1 reference

12 December 2020

Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release

1 reference

12 December 2020

Reduced stress-induced hyperthermia in mGluR5 knockout mice

1 reference

12 December 2020

Effects of D-cycloserine on extinction: translation from preclinical to clinical work

1 reference

12 December 2020

Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5.

1 reference

12 December 2020

Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent

1 reference

12 December 2020

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

1 reference

12 December 2020

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

1 reference

12 December 2020

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

1 reference

12 December 2020

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

1 reference

12 December 2020

Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins

1 reference

12 December 2020

Opposite influence of MPEP, an mGluR5 antagonist, on the locomotor hyperactivity induced by PCP and amphetamine

1 reference

12 December 2020

Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy

1 reference

12 December 2020

Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia

1 reference

12 December 2020

Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice

1 reference

12 December 2020

Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex

1 reference

12 December 2020

Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine

1 reference

12 December 2020

The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity

1 reference

12 December 2020

Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors

1 reference

12 December 2020

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression

1 reference

12 December 2020

Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats

1 reference

12 December 2020

No evidence for association between polymorphisms in GRM3 and schizophrenia

1 reference

12 December 2020

mGluR5 stimulates gliotransmission in the nucleus accumbens.

1 reference

12 December 2020

Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings

1 reference

12 December 2020

Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy

1 reference

12 December 2020

Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders

1 reference

12 December 2020

Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression

1 reference

12 December 2020

Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats

1 reference

12 December 2020

Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia

1 reference

12 December 2020

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

1 reference

12 December 2020

Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia

1 reference

12 December 2020

Activation of group II metabotropic glutamate receptors induces depotentiation in amygdala slices and reduces fear-potentiated startle in rats

1 reference

12 December 2020

Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia

1 reference

12 December 2020

Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia

1 reference

12 December 2020

Antidepressant effects of ketamine in depressed patients

1 reference

12 December 2020

The NMDA receptor as a therapeutic target in major depressive disorder

1 reference

12 December 2020

Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.

1 reference

12 December 2020

The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats

1 reference

12 December 2020

Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands

1 reference

12 December 2020

Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses

1 reference

12 December 2020

Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats.

1 reference

12 December 2020

Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice

1 reference

12 December 2020

Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia

1 reference

12 December 2020

Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells

1 reference

12 December 2020

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

1 reference

12 December 2020

Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary-adrenal axis and noradrenergic function

1 reference

12 December 2020

DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study

1 reference

12 December 2020

Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP.

1 reference

12 December 2020

Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects

1 reference

12 December 2020

Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders

1 reference

12 December 2020

Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine

1 reference

12 December 2020

Lack of the antianxiety-like effect of (S)-3,4-DCPG, an mGlu8 receptor agonist, after central administration in rats

1 reference

12 December 2020

LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats

1 reference

12 December 2020

The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia.

1 reference

12 December 2020

Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test

1 reference

12 December 2020

Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests.

1 reference

12 December 2020

Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs

1 reference

12 December 2020

Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia

1 reference

12 December 2020

Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia

1 reference

12 December 2020

An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats

1 reference

12 December 2020

Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist

1 reference

12 December 2020

The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia

1 reference

12 December 2020

Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex

1 reference

12 December 2020

Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.

1 reference

12 December 2020

Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems

1 reference

12 December 2020

Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders

1 reference

12 December 2020

Lifetime comorbidity of panic attacks and major depression in a population-based study. Symptom profiles.

1 reference

12 December 2020

Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia

1 reference

12 December 2020

Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective

1 reference

12 December 2020

Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice

1 reference

12 December 2020

The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing

1 reference

12 December 2020

Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results

1 reference

12 December 2020

Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment

1 reference

12 December 2020

Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus.

1 reference

12 December 2020

Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization

1 reference

12 December 2020

Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat.

1 reference

12 December 2020

Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals

1 reference

12 December 2020

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).

1 reference

12 December 2020

Modulation of defensive responses and anxiety-like behaviors by group I metabotropic glutamate receptors located in the dorsolateral periaqueductal gray

1 reference

12 December 2020

Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608).

1 reference

12 December 2020

The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison

1 reference

12 December 2020

LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine

1 reference

12 December 2020

No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population

1 reference

12 December 2020

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

1 reference

12 December 2020

AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist

1 reference

12 December 2020

Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia

1 reference

12 December 2020

No evidence for association between a non-synonymous polymorphism in the gene encoding human metabotropic glutamate receptor 7 and schizophrenia

1 reference

12 December 2020

Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP.

1 reference

12 December 2020

Mood disorders: regulation by metabotropic glutamate receptors

1 reference

12 December 2020

Glial reduction in the subgenual prefrontal cortex in mood disorders

1 reference

12 December 2020

Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine

1 reference

12 December 2020

mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.

1 reference

12 December 2020

N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability

1 reference

12 December 2020

Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder

1 reference

12 December 2020

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla

1 reference

12 December 2020

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy

1 reference

12 December 2020

Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans

1 reference

12 December 2020

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

1 reference

12 December 2020

Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus

1 reference

12 December 2020

Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

1 reference

12 December 2020

Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions

1 reference

12 December 2020

Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.

1 reference

12 December 2020

Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways

1 reference

12 December 2020

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions

1 reference

12 December 2020

Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist

1 reference

12 December 2020

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

1 reference

12 December 2020

Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome

1 reference

12 December 2020

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

1 reference

12 December 2020

Involvement of the metabotropic glutamate receptor mGluR5 in NMDA receptor-dependent, learning-facilitated long-term depression in CA1 synapses

1 reference

12 December 2020

On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants

1 reference

12 December 2020

The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam

1 reference

12 December 2020

Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS).

1 reference

12 December 2020

Glutamate as a therapeutic target in psychiatric disorders

1 reference

12 December 2020

The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration

1 reference

12 December 2020

NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR.

1 reference

12 December 2020

Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder

1 reference

12 December 2020

Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons

1 reference

12 December 2020

Riluzole in the treatment of mood and anxiety disorders

1 reference

12 December 2020

Self-medication of anxiety disorders with alcohol and drugs: Results from a nationally representative sample

1 reference

12 December 2020

Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex

1 reference

12 December 2020

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress

1 reference

12 December 2020

Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test

1 reference

12 December 2020

Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes.

1 reference

12 December 2020

The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles

1 reference

12 December 2020

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia

1 reference

12 December 2020

The potential role of lamotrigine in schizophrenia

1 reference

12 December 2020

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

1 reference

12 December 2020